The FDA has accepted a supplemental biologics license application from Regeneron for a 12-week dosing interval of Eylea for patients with wet age-related macular degeneration, the company announced in a press release.
Currently, the recommended dose of Eylea (aflibercept) for wet AMD is a 2-mg injection every 8 weeks after three initial monthly injections.
An integrated analysis of 2-year results from the VIEW 1 and VIEW 2 phase 3 trials found that 51% of patients who had dosing intervals extended to every 12 weeks at the beginning of the second (Read more...)
Uncategorized